All In Biotech

Drug Trial Radar · NCT05816395

Safety and Efficacy of RHH646 for Knee Osteoarthritis

A Randomized, Placebo Controlled, Investigator and Participant-blinded Study Investigating Safety, Tolerability, and Efficacy of RHH646 in Participants With Knee Osteoarthritis

Last checked: Nov 19, 2026Latest source record: Mar 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

82

Actual

Start

May 31, 2023

Primary completion

Feb 24, 2025

Study completion Feb 24, 2025

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Apr 18, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 35 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to evaluate the articular cartilage-regenerating capacity of RHH646 in the knee as well as to assess safety and tolerability in participants with knee osteoarthritis.

Conditions

  • Osteoarthritis, Knee

Interventions

  • RHH646Drug

    RHH646 capsule for oral use

  • PlaceboDrug

    RHH646 placebo capsule for oral use

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Cartilage Volume in the Index Region of the Target Knee by MRITime frame: Baseline, Week 52
  2. Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Adverse events were reported from first dose of study treatment until end of study treatment plus follow up period, up to a maximum duration of approximately 56 weeks.

Locations

10 sites in 5 countries. Site status is shown where the registry gives one.

  • Clinical Trials Research

    Lincoln, California

  • Conquest Research

    Winter Park, Florida

  • Clinical Trial Network

    Houston, Texas

  • Pioneer Research Solutions

    Sugar Land, Texas

  • Novartis Investigative Site

    Buenos Aires, Argentina

  • Novartis Investigative Site

    Caba, Argentina

  • Novartis Investigative Site

    Gandrup, Denmark

  • Novartis Investigative Site

    Herlev, Denmark

  • Novartis Investigative Site

    Warsaw, Poland

  • Novartis Investigative Site

    Santiago, A Coruna, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.